1. Home
  2. CLSD

as 06-18-2024 9:30am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Founded: 2011 Country:
United States
United States
Employees: N/A City: ALPHARETTA
Market Cap: 88.2M IPO Year: 2016
Target Price: $4.80 AVG Volume (30 days): 235.4K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.55 EPS Growth: N/A
52 Week Low/High: $0.65 - $2.12 Next Earning Date: 08-12-2024
Revenue: $8,452,000 Revenue Growth: 758.94%
Revenue Growth (this year): -92.78% Revenue Growth (next year): 618.34%

CLSD Daily Stock ML Predictions

Stock Insider Trading Activity of Clearside Biomedical Inc. (CLSD)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
YERXA BENJAMIN R CLSD Director May 15 '24 Buy $1.31 7,813 $10,235.03 17,957 SEC Form 4
Chong Ngai Hang Victor CLSD CHIEF MEDICAL OFFICER Mar 20 '24 Buy $1.60 30,000 $48,000.00 30,000 SEC Form 4
WHITMORE BRADFORD T CLSD 10% Owner Feb 7 '24 Buy $1.35 444,444 $599,999.40 4,495,034 SEC Form 4
Deignan Charles A. CLSD Chief Financial Officer Jan 18 '24 Sell $1.28 12,900 $16,512.00 384,662 SEC Form 4
LASEZKAY GEORGE M CLSD CEO Jan 18 '24 Sell $1.27 18,000 $22,860.00 466,577 SEC Form 4

Share on Social Networks: